Clearmind licenses psychedelic compounds for mental disorders
License out/inClinical Study
Preview
Source: Pharmaceutical Technology
Clearmind will develop Generation 3.0 psychedelic compounds for treating addiction and mental disorders. Credit: Shyntartanya / Shutterstock.com.
Clearmind Medicine has entered an exclusive licensing agreement with the Yissum Research Development Company of the Hebrew University of Jerusalem to advance the development of Generation 3.0 psychedelic compounds for treating mental disorders.
This move signifies a key advancement in the field of psychedelic therapeutics, particularly for addiction and mental health treatments.
Clearmind will hold exclusive global rights for the development, research, manufacturing, marketing and commercialisation of products obtained from the synthesis of psychedelic compounds.
The strategic partnership will enhance Clearmind’s novel portfolio in addiction and mental disorders.
Clearmind is focused on the discovery and development of new psychedelic-derived therapeutics to manage health issues such as alcohol use disorder (AUD).
See Also:
OncoX inks licensing deal worth over $26m for NSCLC therapy
Preview
Source: Pharmaceutical Technology
Tenaya Therapeutics gets grant for compound for treating diseases by inhibiting HDAC6 activity
Preview
Source: Pharmaceutical Technology
The company is working on transforming psychedelic-based compounds into regulated medicines, foods or supplements through research and development.
Its intellectual property (IP) portfolio comprises sixteen patent families.
Clearmind CEO Dr Adi Zuloff-Shani stated: “We believe that these new generation 3.0 compounds hold enormous therapeutic potential, as well as a strong safety profile.”
“The exclusive licensing agreement with Yissum expands our IP portfolio of highly differentiated assets, strengthens our leadership position with potentially first-in-class assets and illustrates our ongoing commitment to innovation.”
Last month, the company received approval from the Israeli Ministry of Health to begin its Phase I/IIa clinical trial of the 5-methoxy-2-aminoindane-based CMND-100 oral capsule for AUD.
This multinational, multi-centre, single and multiple-dose trial will conduct a comprehensive assessment of the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and AUD subjects.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.